New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 13, 2014
07:08 EDTAKRXAkorn price target raised to $33 from $30 at Piper Jaffray
Piper Jaffray raised its price target for Akorn shares to $33 to reflect the company's acquisition of VersaPharm. Piper believes Akorn has one of the most attractive long-term growth profiles in the broader specialty pharma space and it keeps an Overweight rating on the stock.
News For AKRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 12, 2016
08:46 EDTAKRXAkorn remains a potential takeout target, says RBC Capital
RBC Capital analyst Randall Stanicky says he remains optimistic that Akorn (AKRX) can complete the audit process by May 9 and that the company remains a potential takeout candidate despite one less near-term buyer in Mylan (MYL). Mylan's purchase of Meda puts a potential buyer on the sidelines for now, Stanicky tells investors in a research note. He had viewed Mylan as the most likely suitor followed by Perrigo (PRGO). Applying the price paid for Meda yields a $47 per share buyout price target for Akorn, the analyst notes. He lowered his price target for Akorn shares to $37 from $52 and keeps an Outperform rating on the name.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use